NCT04741178 (Paesi-COV-19) is a clinical trial in Covid19, sponsored by Morgagni Pierantoni Hospital.

Who is sponsoring NCT04741178?

NCT04741178 is sponsored by Morgagni Pierantoni Hospital.

Is NCT04741178 still recruiting?

NCT04741178 is currently status unknown. Last updated 10 February 2021.

Last reviewed 2021-02-10 · How we verify

NCT04741178: Paesi-COV-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PAtterns and Extension in COVID-19 Related Interstitial Pneumonia: CT Analysis

Status unknown Last updated 10 February 2021

What this trial tests

trial in Covid19 in 600 participants. Status unknown.

Timeline

20 March 2020

Primary endpoint
2 January 2021

31 December 2021

Quick facts

Lead sponsor	Morgagni Pierantoni Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	600
Start date	20 March 2020
Primary completion	2 January 2021
Estimated completion	31 December 2021
Sites	1 location across Italy

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Morgagni Pierantoni Hospital

Who can join

Adults 18 to 90, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hallmark of the L phenotype is the vasoplegia, as confirmed by the rapid change in density and distribution of CT findings from the supine to the prone position. The benefit of a prone position in awake, nonintubated, spontaneously breathing Covid-19 patients has been emerging as potential tool to improve oxygenation and to prevent the access to ICU. No evidence of radiological modifications related to Aim of our study is to evaluate CT changes in terms of extension, distribution and prevalence of findings, in the supine compared with the prone position.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Supine vs prone position in mild to moderate COVID-19 pneumonia: The impact of proning on computed tomography findings.
Piciucchi S, Garo ML, Tomassetti S, Ravaglia C, et al · · 2022 · PMID 35738975 · DOI 10.1016/j.ejim.2022.06.012

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04741178 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Morgagni Pierantoni Hospital
Last refreshed: 10 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04741178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing